コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 molecular and cellular mechanisms, however, remain poorly defined.
2 bioactive cargos to TMVs at the cell surface remain poorly defined.
3 ver, the pathways controlling actin networks remain poorly defined.
4 proteins that mediate this protective effect remain poorly defined.
5 ffecting the accuracy of preoperative 4D-CTs remain poorly defined.
6 sis (HCC), but the upstream signaling events remain poorly defined.
7 l nicotinic acetylcholine receptors (nAChRs) remain poorly defined.
8 arsenic and the associated immune mechanisms remain poorly defined.
9 or admission to the ICU and adverse outcomes remain poorly defined.
10 unctional properties of this T cell response remain poorly defined.
11 h mechanical stimuli regulate mTOR signaling remain poorly defined.
12 carditis, yet their identities and functions remain poorly defined.
13 sensitivity to mismatched sequences in vivo remain poorly defined.
14 omo-1 expression and its regulatory activity remain poorly defined.
15 However, the signaling properties of GPR124 remain poorly defined.
16 events in natural oral poliovirus infection remain poorly defined.
17 lar effectors underlying tumor dissemination remain poorly defined.
18 ble polyubiquitin chains on their substrates remain poorly defined.
19 ctors that initiate DLK/JNK pathway activity remain poorly defined.
20 butions of other types of commensal microbes remain poorly defined.
21 al cell lineage relationships that currently remain poorly defined.
22 astoma metastasis although precise functions remain poorly defined.
23 ty, the mechanisms regulating its expression remain poorly defined.
24 echanisms regulating the global SUMO balance remain poorly defined.
25 molecular players governing this transition remain poorly defined.
26 d cell biological consequences of AMPylation remain poorly defined.
27 NDK activity or alternative mechanisms that remain poorly defined.
28 Essential aspects of ultrafiltration remain poorly defined.
29 r antigens targeted in successful treatments remain poorly defined.
30 e specific species associated with GVHD risk remain poorly defined.
31 However, the mechanisms leading to swelling remain poorly defined.
32 alpha), but the cellular actions of XLalphas remain poorly defined.
33 pancreatic cancer progression and metastasis remain poorly defined.
34 However, the key drivers of this process remain poorly defined.
35 ugh the cellular contributors to CNS disease remain poorly defined.
36 ces, and therapeutic options related to FALD remain poorly defined.
37 the metabolic requirements for this process remain poorly defined.
38 r most their organisation and cellular roles remain poorly defined.
39 atures that constitute an effective response remain poorly defined.
40 cular components that stabilize basal bodies remain poorly defined.
41 ity but the mechanisms of IL-36Ra activation remain poorly defined.
42 the clinical and biological features of WDSM remain poorly defined.
43 ing logic governing these concurrent changes remain poorly defined.
44 isorders, although the underlying mechanisms remain poorly defined.
45 the sources and regulation of these signals remain poorly defined.
46 distinctive role in the inflammatory process remain poorly defined.
47 terogeneity of DNA methylation among tumours remain poorly defined.
48 brane traffic, but the underlying mechanisms remain poorly defined.
49 for the action of ROS in intestinal diseases remain poorly defined.
50 defects of antimycobacterial immunity, which remain poorly defined.
51 cruitment mechanisms to the abdominal cavity remain poorly defined.
52 xogenous cells best heal orthopedic injuries remain poorly defined.
53 tem, yet the pathways specifying these fates remain poorly defined.
54 long-term outcomes after surgical resection remain poorly defined.
55 echanisms underlying these sensory functions remain poorly defined.
56 in the mammalian small intestinal epithelium remain poorly defined.
57 or and its regulation by drug-like compounds remain poorly defined.
58 ecular determinants of variability therefore remain poorly defined.
59 ation, and effects of cohesin ubiquitination remain poorly defined.
60 rs that mediate their developmental function remain poorly defined.
61 h Ras can promote such a senescent phenotype remain poorly defined.
62 erning T-bet and CD11c expression in B cells remain poorly defined.
63 sponse to respiratory cryptococcal challenge remain poorly defined.
64 outcomes for pulmonary artery (PA) stenting remain poorly defined.
65 l virulence factors initiate these responses remain poorly defined.
66 molecular mechanisms that drive this process remain poorly defined.
67 itness in epidemiological settings, however, remain poorly defined.
68 they affect the dynamics of subunit joining, remain poorly defined.
69 3 or ILC2s at surfaces such as the intestine remain poorly defined.
70 s is in its infancy and reasonable practices remain poorly defined.
71 aria, but the molecular and cellular details remain poorly defined.
72 of and response to this respiratory pathogen remain poorly defined.
73 rgo recognition of mono-ubiquitinated cargos remain poorly defined.
74 ne transcription, but the molecular pathways remain poorly defined.
75 extracranial systemic embolic events (SEEs) remain poorly defined.
76 molecular pathways driving postmitotic fates remain poorly defined.
77 disease in patients with kidney transplants remain poorly defined.
78 ction of this hyporesponsive state, however, remain poorly defined.
79 tabolic and molecular control of hypertrophy remain poorly defined.
80 ver, the mechanisms controlling AIS assembly remain poorly defined.
81 key features of this immune-mediated process remain poorly defined.
82 that regulate mTOR activity for myelination remain poorly defined.
83 orces that influence hematopoietic potential remain poorly defined.
84 ing its spread in the respiratory epithelium remain poorly defined.
85 observed in many human diseases and ageing, remain poorly defined.
86 atic steatosis, but the potential mechanisms remain poorly defined.
87 but molecular mechanisms of tumor resistance remain poorly defined.
88 ing adaptation to the brain microenvironment remain poorly defined.
89 metformin arrests cancer cell proliferation remain poorly defined.
90 The mechanisms underlying fetal lung injury remain poorly defined.
91 R promotes resistance or disease progression remain poorly defined.
92 ting energetics and longevity across tissues remain poorly defined.
93 isoxazolepropionic acid receptor (AMPAR-Abs) remain poorly defined.
94 tionships among Igh transcriptional elements remain poorly defined.
95 r, the signals instructing these adaptations remain poorly defined.
96 vaccine exists and correlates of protection remain poorly defined.
97 nisms by which H2O2 increases OPN expression remain poorly defined.
98 bolic requirements that support this process remain poorly defined.
99 enic program at central cholinergic synapses remain poorly defined.
100 lth, and rapidly activate reactive responses remain poorly defined.
101 ath mediates immune defense against Yersinia remain poorly defined.
102 prion protein (e.g. PrP(Sc) or PrP-Scrapie) remain poorly defined.
103 vary widely, and patient selection criteria remain poorly defined.
104 ific phenotype of SECs and development of SC remain poorly defined.
105 ng autoimmune disease in PKCdelta deficiency remain poorly defined.
106 stone posttranslational modifications (PTMs) remain poorly defined.
107 ression of genes required in these processes remain poorly defined.
108 actors associated with outcome after surgery remain poorly defined.
109 ge activation and their functional phenotype remain poorly defined.
110 However, the underlying molecular mechanisms remain poorly defined.
111 acteristics and treatment of many AFI agents remain poorly defined.
112 recurrent AF is common and its risk factors remain poorly defined.
113 ading to HCC following chronic HCV infection remain poorly defined.
114 B regulate Ag-specific intestinal Th17 cells remain poorly defined.
115 responses to injury, but upstream activators remain poorly defined.
116 n cellular susceptibility to prion infection remain poorly defined.
117 The molecular mechanisms of emphysema remain poorly defined.
118 sease in the CNS during sterile inflammation remain poorly defined.
119 but the mechanisms mediating these functions remain poorly defined.
120 onocytes into profibrotic macrophages (Mphi) remain poorly defined.
121 ow the ribosome binds these upstream regions remain poorly defined.
122 cells promote human colorectal cancer (CRC) remain poorly defined.
123 ancy, but mechanisms linking these phenomena remain poorly defined.
124 pulations over time in an autoimmune process remain poorly defined.
125 tional relationships with other immune cells remain poorly defined.
126 athways for misfolded mitochondrial proteins remain poorly defined.
127 l patient's risk of malignant transformation remain poorly defined.
128 in an inflammatory milieu over normal HSPCs remain poorly defined.
129 r relationship to threat-responsive circuits remain poorly defined.
130 cellular, and molecular mechanisms involved remain poorly defined.
131 hanisms and translatability to human disease remain poorly defined.
132 nuclear proteins within multinucleated cells remain poorly defined.
133 athways leading to neuropsychiatric diseases remain poorly defined.
134 quiring intensive care unit (ICU) treatment, remain poorly defined.
135 of such inflammation in disease pathogenesis remain poorly defined.
136 ntake, energy balance, and metabolic control remain poorly defined.
137 ivating, the potential roles played by C5aR2 remain poorly defined.
138 obesity, although the underlying mechanisms remain poorly defined.
139 sequent activation of inflammatory pathways, remain poorly defined.
140 m latent (LTBI) to active pulmonary TB (PTB) remain poorly defined.
141 Yet, their roles in skeletal muscle remain poorly defined.
142 ily diversity and regulatory network overlap remain poorly defined.
143 events that initiate type 2 immune responses remain poorly defined.
144 rdiomyopathies, but the molecular mechanisms remain poorly defined.
145 the human genome, but the genes they control remain poorly defined.
146 les for kindlin-1 beyond integrin activation remain poorly defined.
147 , the switch from growth to rapid shrinking, remain poorly defined.
148 iciency with which splice sites are utilized remain poorly defined.
149 chain alcohols and how they mediate a cutoff remain poorly defined.
150 D2 may influence critical cellular processes remain poorly defined.
151 sensory and affective integration, however, remain poorly defined.
152 y a role in Alzheimer's disease pathogenesis remain poorly defined.
153 but the molecular hallmarks of tumor hypoxia remain poorly defined.
154 ctors responsible for such exclusive control remain poorly defined.
155 ous TB vaccine bacille Calmette-Guerin (BCG) remain poorly defined.
156 se NKT2 cells to constitutively produce IL-4 remain poorly defined.
157 t the underlying mechanisms of these enzymes remain poorly defined.
158 gnition events leading to ubiquitin transfer remain poorly defined.
159 cells' becoming dependent on NAD(+) salvage remain poorly defined.
160 t complex step in the metastatic cascade(4), remain poorly defined.
161 imit inflammasome-dependent immune responses remain poorly defined.
162 chanisms that underlie these durable changes remain poorly defined.
163 unctional bowel diseases, but the mechanisms remain poorly defined.
164 fluence neuronal activity and host behaviour remain poorly defined.
165 NE transdifferentiation and their plasticity remain poorly defined.
166 lling their production and diverse functions remain poorly defined.
167 n has a physiological role during infection, remain poorly defined.
168 governing the formation of these protrusions remain poorly defined.
169 e contribution of ZO-1 to cardiac physiology remains poorly defined.
170 ss that characterizes epithelial restitution remains poorly defined.
171 assembly and disassembly in mammalian cells remains poorly defined.
172 ty appear to be well understood, its regulon remains poorly defined.
173 ic pathogens, but its impact on pathogenesis remains poorly defined.
174 le of the immunoproteasome in neuropathology remains poorly defined.
175 ature brain, the role of Sema7A in the adult remains poorly defined.
176 siology of tumors without MYCN amplification remains poorly defined.
177 mmune suppression, but their clinical impact remains poorly defined.
178 he biochemical function of such organization remains poorly defined.
179 nsfusion) on perioperative surgical outcomes remains poorly defined.
180 proteins within the organelle in most cases remains poorly defined.
181 e contribution of individual enteropathogens remains poorly defined.
182 ource of bone-forming cells in these lesions remains poorly defined.
183 molecular architecture of a GPCR/GRK complex remains poorly defined.
184 how these proteins function mechanistically remains poorly defined.
185 ptional network that controls these patterns remains poorly defined.
186 , the physiological role of the CD1 proteins remains poorly defined.
187 s explored for vaccine, the underlying event remains poorly defined.
188 ough the mechanistic basis of discrimination remains poorly defined.
189 ponse contributes to inflammatory regulation remains poorly defined.
190 e proportion of the population, its etiology remains poorly defined.
191 , the role of this subcellular translocation remains poorly defined.
192 ytes grow and integrate into neural circuits remains poorly defined.
193 ignalling pathways and epigenetic regulators remains poorly defined.
194 organic dust exposure independent of smoking remains poorly defined.
195 nscriptional logic underpinning this process remains poorly defined.
196 akaryocyte-erythroid progenitor (MEP), which remains poorly defined.
197 underpinning its reversible deubiquitination remains poorly defined.
198 lying TOT preferential recruitment of the ER remains poorly defined.
199 lly modify SV pools to match network demands remains poorly defined.
200 interactions with the intestinal epithelium remains poorly defined.
201 e of autophagy in doxorubicin cardiomyopathy remains poorly defined.
202 ients undergoing surgery (surgical patients) remains poorly defined.
203 However, the mechanism of this process remains poorly defined.
204 entiations on Ag processing and presentation remains poorly defined.
205 ification in renal transplant patients still remains poorly defined.
206 multiple time scales, and their relationship remains poorly defined.
207 these processes are mechanistically related remains poorly defined.
208 The molecular mechanism for this association remains poorly defined.
209 father's diet has on his offspring's health remains poorly defined.
210 cell function but its role in lymphoid cells remains poorly defined.
211 sm by which TNFalpha promotes neuronal death remains poorly defined.
212 tential can be used for therapeutic purposes remains poorly defined.
213 s, but its function in adult skeletal muscle remains poorly defined.
214 nic impairment and the prognosis of ischemia remains poorly defined.
215 ough the exact cause and effect relationship remains poorly defined.
216 owever, its role in modulating IFN responses remains poorly defined.
217 e regulatory network whose precise circuitry remains poorly defined.
218 , but the physical basis for these reactions remains poorly defined.
219 , the life span of individual memory B cells remains poorly defined.
220 cells (Tregs), but the underlying mechanism remains poorly defined.
221 s, the role of B cells in cutaneous immunity remains poorly defined.
222 own upstream regulators of the Hippo pathway remains poorly defined.
223 , the spatiotemporal organization of mitosis remains poorly defined.
224 nged (EVI1-r) acute myeloid leukemias (AMLs) remains poorly defined.
225 t the underlying logic of these interactions remains poorly defined.
226 pecific gene regulation during embryogenesis remains poorly defined.
227 y of alphaviruses to induce bone pathologies remains poorly defined.
228 on of hematopoiesis during human development remains poorly defined.
229 l receptor (TCR)-mediated ligand recognition remains poorly defined.
230 cellular function(s) of APOL1 in human cells remains poorly defined.
231 -bet in infections with differential outcome remains poorly defined.
232 in people living with HIV-1 infection (PLWH) remains poorly defined.
233 but its role in vegetative tissues of plants remains poorly defined.
234 he initiation and progression of the disease remains poorly defined.
235 fluence memory CD8(+) T cell differentiation remains poorly defined.
236 the relationship between these two mediators remains poorly defined.
237 role in enteropathogenic bacterial infection remains poorly defined.
238 how they are impacted by enteric infections remains poorly defined.
239 igration, the downstream signaling mechanism remains poorly defined.
240 network during chronic herpesvirus infection remains poorly defined.
241 ivity against multiple variants of the virus remains poorly defined.
242 enic stimulation impairs T cell self-renewal remains poorly defined.
243 matopoietic stem cell (HSC) differentiation, remains poorly defined.
244 e mechanism and regulation of this transport remains poorly defined.
245 d interplay between both cell death pathways remains poorly defined.
246 osis (MS), yet their role in MS pathogenesis remains poorly defined.
247 or cell adhesion to the extracellular matrix remains poorly defined.
248 ious cancers, its function in ovarian cancer remains poorly defined.
249 how such responses are negatively regulated remains poorly defined.
250 ss, the relationship between these phenomena remains poorly defined.
251 chanism linking the variant to liver disease remains poorly defined.
252 ssed by other ILC subsets where its function remains poorly defined.
253 The mechanism of this functional switch remains poorly defined.
254 ease progression in children and adolescents remains poorly defined.
255 ods, much of the regulatory noncoding genome remains poorly defined.
256 but its molecular architecture has thus far remained poorly defined.
257 e research, the functions of Hxt8-Hxt17 have remained poorly defined.
258 he molecular nature of this relationship has remained poorly defined.
259 se (pol) theta, an A family polymerase, have remained poorly defined.
261 and function of the tumor immune environment remain poorly defined and need investigation, particular
262 estinal disorders (FGIDs), though mechanisms remain poorly defined and treatment involves non-specifi
263 tion of peptides derived from exogenous Ags, remains poorly defined and may vary with the nature of t
264 identified, the detailed molecular mechanism remains poorly defined and requires further clarificatio
265 ertebrate species, their mechanism of action remains poorly defined and their role in vivo unknown.
266 nship between age and physiological function remains poorly defined and there are no physiological ma
267 r, the molecular mechanisms driving cachexia remain poorly defined, and there are currently no approv
268 the importance of golgin-mediated tethering remains poorly defined, and alternative functions for go
269 l crosstalk between glioblastoma and neurons remains poorly defined, as the mechanisms that underlie
272 cription by human RNA polymerase II (Pol II) remain poorly defined due to a lack of quantitative appr
273 studied, regulatory pathways and mechanisms remain poorly defined due to a lack of suitable readout
274 ich PriC drives DNA replication restart have remained poorly defined due to the limited structural in
275 and unwinding via molecular mechanisms that remain poorly defined for most enzyme subfamilies within
276 getative trapping and particle flocculation, remains poorly defined for microplastics land to sea tra
277 various clinically presenting patient groups remains poorly defined for reasons including that somati
278 r, the prognosis of young-onset colon cancer remains poorly defined given significant age-related dem
279 which are critical for long-term protection, remain poorly defined, impeding our understanding of nat
280 t mechanisms that transmit this form of pain remain poorly defined in both the clinic and preclinical
283 nd pinpoint disease-associated variants that remain poorly defined in their mechanism of action.
284 echanisms underlying this multifunctionality remain poorly defined in vivo Using telencephalon develo
291 epidemiology of campylobacteriosis outbreaks remains poorly defined, largely due to limitations in th
293 n-enveloped virus cell entry, in comparison, remains poorly defined, particularly for large complex c
294 hat underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies ofte
296 al biology of exhausted CD8(+) T cells (Tex) remains poorly defined, restraining improvement of strat
297 for the anti-silencing activity of UCOEs has remained poorly defined, we interrogated various CBX3 su
298 from other ion channels and their structure remains poorly defined, which impedes detailed study of
299 influence the development of cancer, but it remains poorly defined with regard to pancreatic cancer,